Device Trial Radar · NCT05301335
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study
Last checked: Nov 20, 2026Latest source record: Feb 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
126
Actual
Start
May 25, 2022
Primary completion
May 1, 2024
Study completion May 1, 2024
Sponsor
- Lead sponsor
- SpineX Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Rancho Los Amigos National Rehabilitation Center, Downey, California, United States; Atrium Health, Charlotte, North Carolina, United States; MedStar National Rehabilitation Network, Washington, District of Columbia, United States; University of California, San Diego; Craig Hospital, Englewood, Colorado, United States; Columbia University; Institute of Brain and Spine (IBS Hospital), New Delhi, India; International Collaboration On Repair Discoveries (ICORD), Vancouver, British Columbia, Canada; University of Miami, Miami, United States; Mayo Clinic, Rochester, Minnesota, United States; Shepherd Center, Atlanta GA; Spaulding Rehabilitation Hospital, Charlestown, Massachusetts, United States
- First posted
- Mar 29, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness and safety of SCONE neuromodulation therapy after 12 weeks of therapy in comparison to inactive sham control in improving symptoms of Neurogenic Lower Urinary Tract Dysfunction
Conditions
- Neurogenic Bladder
- Spinal Cord Injuries (Complete and Incomplete)
- Stroke
- Multiple Sclerosis
Interventions
SCONEDevice
The Spinal COrd NEuromodulation(SCONE) device delivers a sufficient electrical signal non-invasively to activate the neural structures of the spinal cord without cutaneous discomfort. Rather than relying on stimulation of peripheral nerves, SCONE modulates the CNS directly via the spinal cord. Importantly, SCONE is a technique that enables electrical stimulation of the spinal cord without the need for insertion or implantation of stimulating electrodes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Neurogenic Bladder Symptom Score (NBSS)Time frame: 12 weeks
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Rancho Research Institute
Downey, California
UC San Diego Health Systems
San Diego, California
Craig Hospital
Denver, Colorado
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.